New York, April 28 (RHC)-- A draft manuscript of a report from a long-awaited clinical trial in China finds the antiviral drug remdesivir failed to lower the death rates or recovery times of COVID-19 patients. The findings have not yet passed peer review.
Preliminary results of a study by the New York state Department of Health showed the drug touted by President Trump as a curative for COVID-19 — hydroxychloroquine — had no effect on patients’ recoveries.
